- Home
- ROIV vs PARA Comparison
ROIV vs PARA Comparison
Compare ROIV & PARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- PARA
- Stock Information
- Founded
- ROIV 2014
- PARA 1986
- Country
- ROIV United Kingdom
- PARA United States
- Employees
- ROIV N/A
- PARA N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- PARA Broadcasting
- Sector
- ROIV Health Care
- PARA Industrials
- Exchange
- ROIV Nasdaq
- PARA Nasdaq
- Market Cap
- ROIV 8.4B
- PARA 7.9B
- IPO Year
- ROIV N/A
- PARA N/A
- Fundamental
- Price
- ROIV $10.79
- PARA $11.70
- Analyst Decision
- ROIV Buy
- PARA Sell
- Analyst Count
- ROIV 4
- PARA 13
- Target Price
- ROIV $17.50
- PARA $11.42
- AVG Volume (30 Days)
- ROIV 5.9M
- PARA 7.3M
- Earning Date
- ROIV 05-29-2025
- PARA 05-08-2025
- Dividend Yield
- ROIV N/A
- PARA 1.70%
- EPS Growth
- ROIV N/A
- PARA N/A
- EPS
- ROIV N/A
- PARA N/A
- Revenue
- ROIV $122,585,000.00
- PARA $28,720,000,000.00
- Revenue This Year
- ROIV N/A
- PARA N/A
- Revenue Next Year
- ROIV N/A
- PARA $1.15
- P/E Ratio
- ROIV N/A
- PARA N/A
- Revenue Growth
- ROIV 140.04
- PARA N/A
- 52 Week Low
- ROIV $8.73
- PARA $9.54
- 52 Week High
- ROIV $13.06
- PARA $13.40
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- PARA 53.35
- Support Level
- ROIV $10.58
- PARA $11.74
- Resistance Level
- ROIV $11.77
- PARA $12.08
- Average True Range (ATR)
- ROIV 0.34
- PARA 0.26
- MACD
- ROIV -0.07
- PARA 0.03
- Stochastic Oscillator
- ROIV 17.65
- PARA 60.20
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About PARA Paramount Global Class B
Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.